|Mr. Dror Ben-Asher||Co-Founder, CEO & Director||734.59k||N/A||1966|
|Mr. Gilead Raday MPhil, MSc||Chief Operating Officer||445.38k||N/A||1975|
|Mr. Adi Frish||Chief Corporate & Business Development Officer||419.5k||N/A||1970|
|Mr. Rick D. Scruggs||Chief Commercial Officer, President of RedHill Biopharma Inc. & Director||607.05k||N/A||1960|
|Mr. Razi Ingber||Chief Financial Officer||N/A||N/A||1984|
|Ms. Alexandra Okmian||Senior Business Development & Investor Relations Manager||N/A||N/A||N/A|
|Dr. Reza Fathi Ph.D.||Senior Vice President of Research & Development||299.29k||N/A||1955|
|Mr. Guy Goldberg||Chief Business Officer||338.13k||N/A||1976|
|Dr. June S. Almenoff FACP, M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1957|
|Ms. Patricia Anderson B.Sc. RAC||Senior Vice President of Regulatory Affairs||N/A||N/A||N/A|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.